SEC Form 4 · accession 0001193125-26-265326
Metagenomi Therapeutics, Inc. · MGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Wein
Officer — See Remarks
Period of report
Jun 5, 2026
Accepted (ET)
Jun 10, 2026 · 11:19 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001785279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 5, 2026 | S | 558 | $1.299 | D | 126,491 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.
- F2Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 29, 2026.
Remarks
Title: General Counsel, Compliance Officer and Corporate Secretary